Article Text

PDF

Growth hormone and prolactin stimulation by Madopar in Parkinson's disease
  1. A Martinez-Campos*,
  2. P Giovannini,
  3. E Parati,
  4. A Novelli,
  5. T Caraceni,
  6. EE Müller
  1. Department of Pharmacology, University of Milan, Milan, Italy
  2. Istituto Neurologico C Besta, Milan, Italy

    Abstract

    Madopar, a combination of levodopa with benserazide, induced an inconsistent rise in plasma growth hormone in unmedicated patients with Parkinson's disease and in controls, and a greater growth hormone rise in Parkinsonian subjects on chronic Madopar therapy. In subjects on chronic therapy with levodopa and carbidopa (Sinemet), the growth hormone releasing effect of Madopar was blunted. Madopar increased plasma prolactin (PRL) in controls, unmedicated patients and patients on Madopar therapy while in patients on Sinemet therapy the PRL-releasing effect of Madopar was strikingly reduced. Since these data were interpreted as due to a defective dopamine tone in the hypothalamus of Parkinsonian subjects on Madopar but not Sinemet therapy, a direct dopamine receptor agonist, lisuride was administered. Lisuride, however, elicited a blunted growth hormone response both in patients on Madopar and Sinemet therapy, without revealing a state of supersensitivity of dopamine receptors for growth hormone control in Parkinsonian subjects on Madopar therapy. No difference was present in the PRL-lowering effect of lisuride in the different experimental groups. These findings suggest that: (1) hypothalamic dopamine function is impaired in Parkinsonian subjects on Madopar therapy, preserved in unmedicated patients and enhanced in patients on Sinemet therapy; (2) the endocrine effects observed in Parkinsonian subjects on chronic Madopar therapy may be due to some penetration of benserazide across the blood brain barrier in the region of the hypothalamus; (3) since Madopar and Sinemet are in essence equally effective antiparkinsonian remedies, penetration of benserazide does not occur across the blood brain barrier surrounding the nigrostriatal system.

    Statistics from Altmetric.com

    Footnotes

    • * Conacyt post-doctoral fellow, on leave from the Hospital Universitario “Dr José E Gonzales”, Monterrey, NL Mexico. Present address: Unidad de Medicina Bio Psico Social, Hospital General de Mexico, SSA, Dr Balmis 148, Mexico 7, DF.

      Address for reprint requests: Dr EE Müller, Department of Pharmacology, University of Milan, Via Vanvitelli, 32-20129 Milan, Italy.

      Accepted 1 July 1981

    Request permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.